What are the NCCN guidelines for first-line consolidation therapy for mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


For consolidation therapy, the NCCN recommends the following as first-line:

  • In patients who are candidates for it, high-dose therapy with autologous stem cell rescue (HDT/ASCR), plus rituximab maintenance (category 1 for rituximab maintenance)
  • In patients who are not candidates for HDT/ASCR, rituximab maintenance (category 1 following RCHOP)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!